Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00038272 · ClinicalTrials.gov registry record · Phase 2

A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection

A Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 2
Development phase
56
Enrollment target
17
Study locations

NCT00038272 is a Phase 2 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 56 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The trial reports 17 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00038272, a Phase 2 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 2
Development phase
56 participants
Enrollment target
17
Study locations

Study Summary

The purpose of this study is to evaluate the safety, efficacy, and side effects of beta-D-2,6-diaminopurine dioxolane (DAPD) compared to DAPD plus mycophenolate mofetil (MMF) when these drugs are added to the anti-HIV treatment regimens of people infected with HIV. Some studies have shown that DAPD and MMF can help fight HIV. However, neither DAPD nor MMF has been approved by the Food and Drug Administration for treating HIV infection. This study will help doctors decide if DAPD and MMF are good drugs for treating HIV.

Conditions Studied

HIV Infections

Interventions

  • DRUG Mycophenolate mofetil
  • DRUG Amdoxovir

Study Locations (17)

California

  • UCLA CARE Center CRS - Los Angeles
  • Stanford CRS - Palo Alto
  • UC Davis Medical Center - Sacramento
  • Univ. of California Davis Med. Ctr., ACTU - Sacramento

Pennsylvania

  • Hosp. of the Univ. of Pennsylvania CRS - Philadelphia
  • Univ. of Pennsylvania Health System, Presbyterian Med. Ctr. - Philadelphia
  • Pitt CRS - Pittsburgh

New York

  • Beth Israel Med. Ctr., ACTU - New York
  • NY Univ. HIV/AIDS CRS - New York

Colorado

  • University of Colorado Hospital CRS - Aurora

Florida

  • Univ. of Miami AIDS CRS - Miami

Hawaii

  • Univ. of Hawaii at Manoa, Leahi Hosp. - Honolulu

Maryland

  • Johns Hopkins Adult AIDS CRS - Baltimore

Minnesota

  • University of Minnesota, ACTU - Minneapolis

Trial Details

FieldValue
Enrollment Target 56 participants
Est. Completion 2006-04
Phase Phase 2

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00038272

The ClinicalTrials.gov registry entry for NCT00038272 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Mycophenolate mofetil is the first listed.

NCT00038272 reports 17 study locations spanning 11 distinct geographic areas - top geographies include California, Pennsylvania, New York.

Frequently Asked Questions

What is clinical trial NCT00038272 about?

NCT00038272 is a clinical study titled "A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection". The purpose of this study is to evaluate the safety, efficacy, and side effects of beta-D-2,6-diaminopurine dioxolane (DAPD) compared to DAPD plus mycophenolate mofetil (MMF) when these drugs are added to the anti-HIV treatment regimens of people infected with HIV. Some studies have shown that DAPD...

What is the current status of trial NCT00038272?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. Estimated completion is 2006-04.

What conditions does trial NCT00038272 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00038272?

The interventions under investigation include: Mycophenolate mofetil (DRUG), Amdoxovir (DRUG).

Who is sponsoring clinical trial NCT00038272?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00038272 being conducted?

This trial has 17 study locations across California, Colorado, Florida, Hawaii, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.